Stock vs Stock Comparison

Abbott Laboratories vs Johnson & Johnson

ABT wins the Tale of the Tape 5–4.

ABT$86.99
JNJ$223.24

🏆 Tale of the Tape

54
ABTJNJ
14.7%Profitability (Net Margin)28.5%
24.0xValuation (P/E)26.1x
10.1%Efficiency (ROIC)18.3%
5/9Health (Piotroski F)4/9
4.9Safety (Altman Z)4.0
5.7%Growth (Rev YoY)6.0%
-1.05Risk (Sharpe 1Y)2.69
0.64xBalance Sheet (D/E)1.44x
4.21%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.304
252-Day Correlation
0.153
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricABTJNJ
Market Cap$149.1B$542.4B
P/E Ratio24.0x26.1x
Forward P/E14.1x17.7x
P/B2.86x6.68x
Dividend Yield2.94%2.38%
Beta0.650.26

Quantitative Metrics

MetricABTJNJ
DCF Fair Value$57.20$134.24
DCF Upside-43.2%-43.6%
Piotroski F5/94/9
Altman Z4.873.97
Beneish M-2.53-2.27
FCF Yield4.21%3.25%
Net Debt/EBITDA0.1x0.5x
ROIC10.1%18.3%
WACC9.4%7.7%
ROIC – WACC0.7pp10.5pp
Gross Margin56.4%67.9%
Net Margin14.7%28.5%
Rev Growth YoY5.7%6.0%
Sharpe (1Y)-1.052.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio56%64%

ABT Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ABT vs JNJ: Head-to-Head Analysis

Abbott Laboratories (ABT) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ABT generates a return on invested capital (ROIC) of 10.1% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ABT and JNJ is 0.304, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

ABT appears in 34 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ABT or JNJ?

Our quantitative analysis compares ABT and JNJ across nine fundamental dimensions. ABT wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ABT and JNJ correlated?

The 252-day correlation between ABT and JNJ is 0.304. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.